The effect of chemotherapy combined with recombination mutant human tumor necrosis factor on advanced cancer

Journal of Translational Medicine

Guoxiang Guang¹  Chuan Wang¹  Changmin Huang¹  Xinyuan Wu¹  Huishan Lu¹  Zhi-weng Zheng¹  Xiang-fu Zhang¹  Xing Liu¹ 

[1] Department of Oncology, Union Hospital of Fujian Medical University, Fujian, Fuzhou, 350001, P. R. China

关键词: Complex therapy;    Chemotherapy;    Biological therapy;    Tumor necrosis factor;    Tumor;   

Others  :  1208529
DOI  :  10.1186/1479-5876-2-33

 received in 2004-05-27, accepted in 2004-10-14,  发布年份 2004

【 摘 要 】

Background

Past studies suggested that tumor necrosis factor (TNF) assisted anti-tumor treatment and intensified the sensitivity of chemotherapy. However its clinical application has been curbed because of its low purity, high dosage, and strong toxicity. This research, through perspective random clinical control experiment, observed the therapeutic effect of the treatment of late malignant tumor through the injection of recombinant mutant human tumor necrosis factor (rmhTNF) combined with general chemotherapy and its adverse reactions.

Methods

105 patients with advanced malignant tumor were randomly divided into trial group, 69 patients, and control group, 36 patients. Injection of rmhTNF 4 × 10⁶u/m² was given to the trial group, from the 1^st to 7^th days, the 11^th to 17^th days combined with chemotherapy course. The chemotherapy plan was as follows: CAP for patients with the NSCLC; FAM for patients with gastric cancer; FC for patients with colorectal cancer. One treatment cycle lasted for 21 days and two cycles were scheduled. The control group was given only the same chemotherapy as the trial group.

Results

In the trial group there was 1 CR case and 12 PR cases, and the response rate is 13/69 (18.84%); in the control group 1 PR case, the response rate 1/36 (2.78%). The response rate of the trial group was significantly higher than that of the control group (P = 0.022). The response rate for NSCLC in the trial group was 8/17 (47.06%), and 1/6 (16.67%) in the control group. The response rates for gastric cancer and colorectal cancer in the trial groups also were higher than those of the control groups. After the treatment the KPS is 89.00 ± 9.92 in the trial group, and 84.17 ± 8.84 in the control group, with a significant difference between the two groups (P = 0.028). The adverse reactions of rmhTNF injection included: pain in the injection area, chill, hardening and swelling and redness in the injection area, fever, ostealgia and myosalgia, and cold-like symptoms. All these adverse reactions were mild and bearable.

Conclusions

The administration of rmhTNF injection in combination with general chemotherapy is an effective and secure means in treating advanced malignant tumor.

【 授权许可】

   
2004 Liu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Xian-Zhong Gao, Shu-Xu Xu: Current diagnosis and therapy of tumors [M]. Beijing, Science and Technology Press; 1973:118.
• [2]Min-Li Huang, Hong Sun, You-ji Feng, et al.: The study of Tumor-Necrosis Factor and chemotherapy on Gynecologic Carcinoma. Chin J Cancer Biother 1995, 2(3):202.
• [3]Lee KY, Chang W, Qiu D, et al.: PG 490 (triptolide) cooperates with tumors necrosis factor alpha to induce apoptosis in tumor cells[J]. J Biol Chem 1999, 274(19):13451-13455.
• [4]Lasek W, Giermasz A, Kuc K, et al.: Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and vivo results[J]. Int J Cancer 1996, 66(3):374-379.
• [5]Libutti SK, Barlett DJ, Franker DL, et al.: Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies[J]. J Am Coll Surg 2000, 191(5):519-530.
• [6]Nakamura S, Kato A, Masegi T, et al.: A novel recombinant tumor necrosis factor alpha mutant with increased anti-tumor activity and lower toxicity[J]. Int J Cancer 1991, 48(5):744-748.
• [7]Kamijo R, Takeda K, Nagumo M, et al.: Induction of differentiation of human monoblastic and myeloblastic leukemia cell lines by TNF muteins[J]. Biochem Biophys Res Commun 1989, 160(2):820-827.
• [8]Zhang ying-qi, Zhao ning, Li bo, et al.: Preparation of a novel recombinant human tumor necrosis factor-α by gene engineering technology[J]. Chin J Cell Mol Immunol 2002, 18(4):402-405.
• [9]Yi Su, Ya-Mei Wu: The study of synergistic cytotoxicity of tumor necrosis factor and interleukin-2 against lung adenocarcinoma cell[J]. Chinese Journal of Cancer 2000, 19(8):779-781.
• [10]Liddil JD, Dorr RT: Schedule dependent toxicity of tumor necrosis factor in rodents. Cancer drug Deliv 1987, 4(3):159-167.
• [11]Budd GT, Green S, Baker LH, et al.: A Southwest Oncology Group phase H trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer 1991, 68(8):1694-1695.
• [12]Schilling PJ, Murray JL, Markowitz AB: Novel tumor necrosis factor toxic effects. Cancer 1992, 69:256-260.